Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
6719 Results for "
Blocker
" in MedChemExpress (MCE) Product Catalog:
Products (6719)
6719 Results for "Blocker" in MCE Product Catalog:
Cat. No.: HY-179041
CAS No.: 924851-91-2
Target:
PGE synthase Prostaglandin Receptor MDM-2/p53 Amino acid Transporter Glutathione Peroxidase Ferroptosis
Research Areas:
SZ0232 is a selective mPGES-2 inhibitor. SZ0232 binds to the active site of mPGES-2 via hydrogen bonds and π-π stacking, reduces the production of prostaglandin E2 (PGE2) and blocks the PGE2-EP3 pathway. SZ0232 regulates Ferroptosis by activating the heme-dependent p53/SLC7A11/GPX4 axis, inhibits lipid peroxidation, and protects renal tubules. SZ0232 enhances glucose-stimulated insulin secretion, inhibits β-cell senescence, and improves glucose homeostasis. SZ0232 reduces renal lipid accumulation, alleviates fibrosis, and ameliorates renal dysfunction in diabetic mice. SZ0232 inhibits renal cyst growth in polycystic kidney disease models. SZ0232 exhibits an insulinotropic effect that strengthens with the increase of animal age. SZ0232 can be used in studies related to type 2 diabetes, acute kidney injury, diabetic kidney disease, and autosomal dominant polycystic kidney disease .
Cat. No.: HY-183684
RET-IN-33 is a moderately selective inhibitor of RET mutants. RET-IN-33 potently inhibits G810 mutants, with IC50 values of 4.43 nM (G810R), 3.28 nM (G810C) and 0.51 nM (G810S), respectively. RET-IN-33 also inhibits other RET mutants: V804M (IC50 0.73 nM), V804L (IC50 0.36 nM), Y806H (IC50 0.74 nM) and M918T (IC50 0.55 nM). RET-IN-33 also inhibits other kinases, with an IC50 of 1.50 nM against VEGFR2 and 1.60 nM against PDGFRα. RET-IN-33 blocks the autophosphorylation of RET mutants and the downstream SHC/AKT/ERK signaling pathway. RET-IN-33 selectively inhibits the proliferation of RET-driven cell models without affecting non-RET-dependent or normal cells. RET-IN-33 exhibits dose-dependent antitumor efficacy in RET-driven xenograft models. RET-IN-33 can be used for the research of medullary thyroid carcinoma, papillary thyroid carcinoma and non-small cell lung cancer .
Cat. No.: HY-18719H
CAS No.: 1032008-71-1
Research Areas:
Endoxifen Z-isomer methanesulfonate is an orally active selective PKCβ1 inhibitor with an IC50 of 360 nM against human PKCβ1. It also acts as an estrogen receptor modulator and antiestrogen. Endoxifen Z-isomer methanesulfonate binds to and blocks ERα, ERβ and PKCβ1, inhibits estrogen and PI3K/AKT/mTORC1 signaling pathways, suppresses the expression of genes associated with cell cycle, cell proliferation and extracellular matrix remodeling, and induces apoptosis, reactive oxygen species (ROS) production and hypoxic features. Endoxifen Z-isomer methanesulfonate inhibits tumor growth in breast tumor and glioblastoma models, reduces bone turnover and blood lipid levels, and does not require metabolism via CYP2D6. It can be used in research related to ER + breast cancer, invasive breast cancer, glioblastoma multiforme, type I bipolar disorder, desmoid tumor, gynecological malignancies, melanoma and hormone receptor-positive solid tumors .
Cat. No.: HY-50896R
CAS No.: 183321-74-6
Synonyms: CP-358774 (Standard); NSC 718781 (Standard); OSI-774 (Standard)
Research Areas:
Erlotinib Standard (CP-358774 Standard) is the analytical standard of Erlotinib (HY-50896). This product is intended for research and analytical applications. Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, as well as the deposition of fibronectin, α-SMA, collagen and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, EGFR inhibitor resistance and renal fibrosis .
Cat. No.: HY-50896S
CAS No.: 1034651-23-4
Synonyms: CP-358774-d6; NSC 718781-d6; OSI-774-d6
Cat. No.: HY-50896S1
CAS No.: 1211107-68-4
Synonyms: CP-358774-13C6; NSC 718781-13C6; OSI-774-13C6
Cat. No.: HY-50896S2
CAS No.: 1130852-41-3
Synonyms: CP-358774-d4; NSC 718781-d4; OSI-774-d4
Cat. No.: HY-50896S3
CAS No.: 1266656-97-6
Synonyms: CP-358774-d8; NSC 718781-d8; OSI-774-d8
Cat. No.: HY-B0331AR
CAS No.: 76095-16-4
Synonyms: MK-421 maleate (Standard)
Target:
Reference Standards Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS)
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease
Enalapril maleate (Standard) (MK-421 maleate (Standard)) is the analytical standard of Enalapril maleate (HY-B0331A). This product is intended for research and analytical applications. Enalapril maleate is an orally active angiotensin-converting enzyme inhibitor. Enalapril maleate blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril maleate inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril maleate attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril maleate reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril maleate is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology .
Cat. No.: HY-B0331S1
CAS No.: 1356847-94-3
Synonyms: MK-421-d3
Cat. No.: HY-B0426AS2
Synonyms: ALO4943A-d6 hydrochloride; KW4679-d6 hydrochloride
Cat. No.: HY-N0515R
CAS No.: 945619-74-9
Cat. No.: HY-N1510
CAS No.: 22149-35-5
Cat. No.: HY-N1746
CAS No.: 270249-38-2
Synonyms: 2'-O-Methylkurarinone
Cat. No.: HY-P990144
Target:
Research Areas:
Cat. No.: HY-P990290
Target:
Research Areas:
Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD16/CD32. Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) is a chimeric antibody of the original 2.4G2 antibody (HY-P99125). Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) contains the LALA-PG mutation region. Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) can block the combination of CD16 and FcγRs. Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) can be used for the researches of immunology and cardiovascular disease.
Cat. No.: HY-P992059
Cat. No.: HY-118594R
CAS No.: 632-93-9
Target:
Research Areas:
Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate (Standard) is the analytical standard of Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate (HY-118594). This product is intended for research and analytical applications. Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate is an orally active porphyrin inducer and ferrochelatase inhibitor. Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate can induce small bile duct obstruction in mice, resulting in blocked bile excretion and causing cholestasis. Long-term use of Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate can cause damage to bile duct epithelial cells, inflammatory responses, and liver fibrosis. Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate can be used to simulate the pathological features of cholestatic liver diseases such as sclerosing cholangitis (PSC).
Cat. No.: HY-13689G
CAS No.: 133053-19-7
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
